Novo Nordisk
Information

Novo Nordisk

ISIN
DK0060534915
Ticker
NOVO B
ISIN
DK0060534915
Ticker
NOVO B
New Post

Information

large cap stock
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Employees
46,982
Industries
Biotechnology & Drugs
Sector
Health Care

Community

Financials

52W Low
$64.21
52W High
$117.99
Market Capitalization
DKK 1.13T
EBITDA
DKK 61.51B
Beta
0.85934

Analyst Ratings

Target Price
DKK 661.21
This security is covered by 30 analysts
Buy
6
Hold
17
Sell
7

Dividends

Activities

Trending